Comparative Pharmacology
Head-to-head clinical analysis: BONIVA versus RECLAST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BONIVA versus RECLAST.
BONIVA vs RECLAST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits bone resorption via binding to hydroxyapatite and inhibiting osteoclast activity.
Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting farnesyl diphosphate synthase (FPPS), a key enzyme in the mevalonate pathway, leading to disruption of osteoclast activity and induction of apoptosis.
150 mg orally once monthly; 2.5 mg orally once daily also approved but less commonly used. Administer on empty stomach with plain water (6-8 oz) at least 60 minutes before first food, beverage, or other medications. Do not lie down for 60 minutes after administration.
5 mg intravenously over at least 15 minutes once yearly for osteoporosis.
None Documented
None Documented
Terminal half-life: 10-60 hours (clinical relevant); long terminal half-life (120-720 hours) due to slow dissociation from bone, supports weekly dosing.
The terminal elimination half-life of zoledronic acid in plasma is approximately 146 hours (range 76-250 hours) due to slow release from bone. Clinically, this supports a once-yearly dosing interval for osteoporosis.
Renal: ~50-60% unchanged in urine; biliary/fecal: ~40-50% eliminated via feces, primarily as unchanged drug.
Primarily renal; unchanged drug is excreted in urine. Approximately 50% of an absorbed dose is excreted unchanged in urine within 24 hours. The remainder is eliminated via renal excretion over an extended period, with negligible fecal or biliary elimination.
Category C
Category C
Bisphosphonate
Bisphosphonate